References
Lai P, Wang Y. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Cancer Biol Med. 2021; 18: 34-51.
Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019; 19: 151-61.
Sheng WQ, LaFleur MW, Nguyen TH, Chen SJ, Chakravarthy A, Conway JR, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018; 174: 549-63.
Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours – past lessons and future promise. Nat Rev Clin Oncol. 2020; 17: 91-107.
Xue Y, GaoYT, Meng FL, LuoL. Recent progress of nanotechnology-based theranostic systems in cancer treatments. Cancer Biol Med. 2021; 18: 336-51.
Zhai YH, Wang JM, Lang TQ, Kong Y, Rong R, Cai Y, et al. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat Nanotechnol. 2021. https://doi.org/10.1038/s41565-021-00972-7.
